drugset / Trial / NCT05623488
CAR T Cells in Mesothelin-Expressing Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 - Safety and Proof of Concept
Timeline
- Start
- 2023-02-06
- Primary completion
- 2025-04-07
- Completion
- 2025-04-07
Outcome
Outcome not reported
Stopped: “Feasibility Concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | huCART-meso cells | Cell therapy | 3e+06 cells | Other |
| Subject | huCART-meso cells | Cell therapy | 3e+07 cells | Other |